|
Reimbursement (EUR)
|
Cases (n = 95)
|
Controls (n = 346)
|
Linear regression with log(reimbursement) as outcome
|
|---|
| |
Median (IQR)
|
Mean (SD)
|
Median (IQR)
|
Mean (SD)
|
Coef
|
95% CI
|
p-value
|
|---|
|
All patients (n = 95/441)
|
5174 (3347–9059)
|
13,233 (26,899)
|
3762 (2405–6669)
|
7198 (18,159)
|
0.37
|
0.19–0.54
|
<0.05
|
|
• No infections (n = 42/227)
|
6423 (3603–8445)
|
13,208 (26,850)
|
3680 (2103–6669)
|
7797 (22,619)
|
0.48
|
0.22–0.74
|
<0.05
|
|
• Any infection (n = 53/214)
|
4560 (3148–11,178)
|
13,252 (27,195)
|
4355 (3148–6326)
|
6511 (11,033)
|
0.21
|
−0.03 – 0.45
|
0.09
|
|
- Non-severe infections (n = 31/131)
|
3450 (2523–5794)
|
8065 (18,243)
|
3347 (2523–5794)
|
5299 (12,802)
|
0.09
|
−0.25 – 0.44
|
0.60
|
|
- Severe infections (n = 15/65)
|
7600 (5794–21,931)
|
26,904 (41,802)
|
7600 (4560–7600)
|
9300 (7268)
|
0.47
|
0.15–0.79
|
<0.05
|
-
IQR Interquartile range, SD Standard deviation, CI Confidence interval, EUR Euro, Exchange rate NOK-EUR7.4805 average for 2012
